We cannot make the conclusion that TLR9, TGF-β1, or PDGF-B antagonists can be used as treatments for LN, though we hypothesize that TLR9, TGF-β1, and PDGF-B may serve as new therapeutic targets for SLE. The gene discussed is PDGFB; the disease is systemic lupus erythematosus.